Bill Gates says the world will be better in 20 years: 'My optimism hasn't been shaken'
Bill Gates has issued some pretty big warnings in recent years — about the next pandemic or avoiding a "climate disaster" — but the billionaire says he's actually very optimistic about the future.
"You can accuse me of being by nature an optimistic person," Gates told The New York Times in an interview that published on Thursday. "But I just think I'm being realistic. I think it's objective to say to you that things will be better in the next 20 years."
Gates' positive outlook comes at a precarious time of geopolitical instability: multiple global conflicts and a trade war that's roiled markets around the world.
Gates himself recently lamented decisions by the U.S. and other world governments to slash tens of billions of dollars in foreign aid, writing in a Thursday blog post that "it's unclear whether the world's richest countries will continue to stand up for its poorest people." He added that "no philanthropic organization ... can make up the gulf in funding that's emerging right now."
Still, Gates is adamant that his "optimism hasn't been shaken," he told the Times. On Thursday, the Microsoft co-founder laid out "ambitious" plans to hand out $200 billion in aid through the Gates Foundation over the next two decades, and then close the foundation down.With those funds, he hopes to reduce preventable deaths of mothers and children around the world, eradicate diseases like polio, malaria, measles and Guinea-worm disease, and help "hundreds of millions of people break free from poverty" by funding advances in education and agriculture in African nations, he wrote in his blog post.
"The truth is, there have never been more opportunities to help people live healthier, more prosperous lives," wrote Gates. "Advances in technology are happening faster than ever, especially with artificial intelligence on the rise."
Gates wishes the world didn't have to rely on AI advancements as a sort of "magic wand" — the billionaire has frequently touted the tech's potential to improve global health and education — but the technology will boost his foundation's ability to reach its goals by 2045, he told the Times.
Gates' optimism isn't solely reliant on AI.
Since 1990, the world's child mortality rate has been more than cut in half, thanks to broader access to advanced medical care, vaccinations and improved nutrition, according to the World Health Organization.
Even after accounting for multiple countries cutting their foreign aid budgets in recent months, new medical advances — from vaccines to nutritional education initiatives — could make inroads toward cutting the child mortality rate in half yet again, Gates wrote in his blog. The same goes for working toward eradicating diseases like malaria and slowing the spread of HIV/AIDS, he added.
Gates also wrote that he's hopeful other billionaires will increase "the pace and scale of their giving," pointing to younger generations of wealthy philanthropists who can pick up the mantle once the Gates Foundation shuts down.
Among them: Meta co-founders Mark Zuckerberg and Dustin Moskovitz, who both signed The Giving Pledge, in which they each publicly promised to give away the bulk of their wealth during their lifetimes. MacKenzie Scott, ex-wife of Jeff Bezos, has become a prominent philanthropist in recent years, giving over $19 billion to hundreds of different organizations since 2019.
"Even with all the challenges that the world faces, I'm optimistic about our ability to make progress — because each breakthrough is yet another chance to make someone's life better," Gates wrote.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
4 hours ago
- Business Insider
South Africa leads as 17 African companies make Forbes list of world's largest firms
For the 23rd consecutive year, Forbes has released its Global 2000 ranking, highlighting the world's largest and most influential publicly traded companies, with South Africa accounting for the majority of Africa's entries. Forbes released its 23rd Global 2000 ranking of the world's largest publicly traded companies in 2025. A total of 17 African companies are on the list, with South Africa leading the entries. South Africa dominated the African representation with firms across finance, tech, mining, chemicals, and more. In 2025, a total of 17 African companies made the Forbes Global 2000 ranking, dominated by South Africa with 14 entries, followed by Morocco with 2 and Egypt with 1. Per Forbes, the 2025 Global 2000 companies collectively account for $52.9 trillion in revenue, $4.9 trillion in profits, $242.2 trillion in assets, and a $91.3 trillion market capitalization. Notably, despite global economic challenges such as renewed U.S. trade tensions, these companies achieved record-breaking figures across all four key metrics: revenue, profit, assets, and market value; showcasing remarkable resilience. 17 African countries ranked within the global top 2,000: RANK Company Country Sector New Gains 1 FirstRand South Africa Banking $2.26 B 2 Standard Bank Group South Africa Banking $2.39 B 3 Naspers South Africa IT software & Services $3.31 B 4 Sanlam South Africa Insurance $1.21 B 5 Absa Group South Africa Banking $1.17 B 6 Attijariwafa Bank Morocco Banking $956 M 7 Nedbank South Africa Banking $926.6 M 8 Old Mutual South Africa Insurance $418.2 M 9 Gold Fields South Africa Materials $ 1.24 B 10 AngloGold Ashanti South Africa Materials $1 B 11 MTN group South Africa Telecom Services $-523.2 M 12 CAPITEC South Africa Insurance $659.1 M 13 International Commercial Bank Egypt Banking $1.1 B 14 Momentum Metropolitan Holdings South Africa Insurance $271.4 M 15 Sasol South Africa Chemicals $ -2.69 B 16 Banque Centrale Populaire Morocco Banking $416.9 M 17 Bid South Africa Hotels, Restaurants & Leisures $433.3 M Africa's representation on the Forbes Global 2000 list may be modest, but there's no doubting its economic influence is steadily growing within and beyond the continent. This is evident in the diverse range of companies featured, from established multinationals to emerging tech and financial powerhouses. South Africa has once again cemented its dominance in Africa's corporate landscape, with the majority of the continent's representatives in the 2025 Forbes Global 2000 list. Out of the 17 African firms that made the cut, 14 are based in South Africa, spanning sectors such as banking, insurance, telecommunications, mining, and chemicals. Leading South Africa's presence are FirstRand, Standard Bank, and Naspers, reflecting the country's strength in finance and tech. Morocco follows distantly with two companies, Attijariwafa Bank and Banque Centrale Populaire, while Egypt's Commercial International Bank (CIB) is the only North African entrant outside Morocco. The exclusion of Nigerian companies from the ranking is concerning. Despite hosting major oil and industrial giants, Nigeria's low number of publicly listed large-cap firms and weak presence in global financial benchmarks limit its corporate visibility, even as Africa's most populous nation.
Health Line
5 hours ago
- Health Line
HIV: As Scientists Inch Closer to a Vaccine, Cuts to Funding Could Stall Progress
The Trump administration reportedly plans to cut almost all funding for HIV vaccine research. Experts say the decision comes at a time when research in this field is making substantial progress. Many effective treatments are available for HIV, but these are lifelong commitments that manage a chronic disease rather than cure it. Treatments for HIV infection have come a long way since the 1980s, when too many lives were lost during the epidemic. Today, antiretroviral therapies and other treatments allow people with HIV to live longer lives and, in many cases, prevent the transmission of the virus that causes the disease to other people. Scientists now say the next step in the fight is a vaccine that protects against HIV. However, that next development could be on the chopping block. Trump administration officials reportedly plan to halt funding for a wide array of HIV vaccine research. Researchers told CBS News they have been informed by officials at the National Institutes of Health (NIH) that the Department of Health and Human Services (HHS) has instructed the agency not to issue any more funding during the next fiscal year for HIV vaccine research. NIH officials said HHS officials have instead decided to 'go with currently available approaches to eliminate HIV.' The decision will close down HIV vaccine research projects at the Duke Human Vaccine Institute and the Scripps Research Institute, according to a report in the journal Science. Officials at Moderna also told CBS News that their current clinical trials on HIV vaccines have been put on hold. Experts say the decision to cut funding for an HIV vaccine is short-sighted and reckless. 'I'm stunned by this decision,' said Jake Scott, MD, a clinical associate professor of medicine at Stanford University in California who specializes in infectious diseases. 'There is no scientific or medical evidence to justify these cuts at the exact moment this field is showing real promise,' he told Healthline. Carl Baloney Jr., the chief executive officer-elect of AIDS United, agreed. 'Eliminating funding for HIV vaccine research undermines decades of scientific progress and turns our back on a future where HIV could be preventable for all, regardless of where someone lives, their income, or access to healthcare,' he told Healthline. Why an HIV vaccine is important Experts say that treatments for HIV are incredibly effective. However, they note that most involve daily adherence and aren't necessarily readily available or affordable for many people. 'There are a lot of good options, but they can be really expensive,' Scott said. 'These medications are also not a cure. They are a lifetime burden.' The experts add that people with low levels of HIV in their system can still have weakened immune systems. That can raise the risk of serious infections as well as inflammation that can lead to conditions such as heart disease. 'A vaccine can help prevent all this,' said Scott. Experts note that a vaccine research program may be difficult to put back together even if a new administration restored funding in the near future. They say it took decades to build these programs and restarting them would take time. In addition, researchers will leave the field of HIV prevention to set up shop in another industry that is receiving funding. 'We could lose an entire generation of scientists,' said Scott. 'This is setting the field back a decade or more at a critical time.' 'This isn't just about canceling [a] clinical trial. It's about sidelining the scientists, institutions, and community partners driving innovation forward,' added Baloney. 'These setbacks could delay the development of a successful HIV vaccine by years or even decades.' How scientists fought against HIV The first treatment for HIV was approved by the Food and Drug Administration (FDA) in 1987. Azidothymidine (AZT) was first developed in 1964 as a treatment for cancer. It was ineffective in that usage, but in the 1980s, scientists discovered AZT could suppress HIV replication without damaging healthy cells. It helped treat people with AIDS as well as people who were HIV positive but had no symptoms. In the 1990s, other nucleoside reverse transcriptase inhibitors (NRTIs) were developed and approved. Laboratory tests to measure viral load and cell counts accelerated this research. From there, scientists experimented with combining drugs to help counter the HIV virus's ability to mutate and replicate. In 1996, a triple-drug therapy proved effective in thwarting HIV replication and creating a barrier against drug resistance. Since then, these antiretroviral drugs have become more effective and more available. The effectiveness of these medications is nothing short of miraculous. In the 1980s, the average life expectancy after an AIDS diagnosis was one year. Today, people who adhere to combination antiretroviral drug therapies can expect to live a near-normal life span. In some cases, the medications can reduce the HIV viral load in a person to the point where the virus is undetectable and can't be transmitted to another person. How is HIV treated today? More than 50 types of HIV medications are now approved for use. Some of the more commonly used antiretroviral medications are: Combination NRTI drugs that include Truvada and Descovy. These medications work by preventing HIV from converting its RNA into DNA. This prevents the virus from making copies of itself.. Integrase strand transfer inhibitors (INSTIs) that include Vocabria and Biktarvy. These drugs work by blocking an enzyme that HIV uses to put HIV DNA into human DNA inside cells. Protease inhibitors (PIs) such as Lexiva and Crixivan. These medications work by blocking an enzyme that HIV needs as part of its life cycle. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) that include Intelence and Viramune. These drugs work by preventing the HIV virus from making copies of itself. Entry inhibitors such as Fuzeon and Selzentry. These medications work by blocking HIV from entering CD4 T cells. In addition, there are drugs known as Cytochrome P4503A (CYP3A) inhibitors, such as Tybost and Norvir, that help boost the levels of HIV medications in the bloodstream. There are also medications known as post-attachment inhibitors that when used with antiretroviral drugs can help prevent HIV from entering immune cells. Trogarzo was the first of these drugs to become available, having been approved in 2018. In addition, there are attachment inhibitor medications, a newer form of HIV drug that works by attaching to a viral protein, which prevents that protein from entering healthy T cells. Only one type of this medication, Rubokia, is currently available, having been approved in 2020. Most people with HIV are given medications, but there also are long-acting injections that are given once a month or once every other month. Scott said these treatments are cures that have turned HIV into a 'managed chronic disease' to the point where he and other colleagues now refer to AIDS as 'advanced HIV.' Baloney said, however, there are limits to how much treatments can do. 'Current treatments and prevention tools have transformed HIV into a manageable chronic condition, but they are not a cure and they're not accessible to everyone,' he said. 'An HIV vaccine would be a game-changer, especially for communities facing systemic barriers to care.' Preventive measures for HIV Even with the available treatments, experts agree that it's better for a person if they don't contract HIV in the first place. They say condom use, along with dental dams and gloves, can be effective barriers to contracting HIV. Limiting sexual partners is also recommended, as are sterile needles for intravenous drug users. Getting tested for HIV is also an important component. It's estimated that more than 1 million people in the United States have HIV, and 13% of them don't know they have contracted the virus. There are medications available that can be taken as a precaution or after potential exposure to HIV. These drugs include: Preexposure prophylaxis (PrEP): These medications can be taken as a daily pill or a bimonthly injection. The first injectable PrEP drug was Apretude, which was approved by the FDA in 2021. Truvada can also be used as PrEP therapy. These medications help prevent HIV from getting a foothold in the body. Postexposure prophylaxis (PEP) drugs: These are designed to be taken within 72 hours of potential exposure to HIV. It is a pill ingested once a day for 28 days. Lenacapavir: This injectable drug has been tested in clinical trials as a potential PrEP therapy. The FDA is scheduled to vote on its approval on June 19. Experts say all these preventive measures are good practices, but they note that vaccines are still the most effective.
New York Post
8 hours ago
- New York Post
Why AI — not DEI — could be society's great equalizer
In companies across America, AI systems are coding software, creating marketing campaigns, and writing legal briefs — jobs that were once reserved for highly educated professionals. The college degree, long touted as the great equalizer, is losing value as algorithms master tasks that take humans years to learn. This isn't some distant scenario; it's happening now, and it will trigger the most profound workplace disruption since the Industrial Revolution. 5 AI will irrevocably change the global workforce, but hit white-collar workers harder than their blue-collar counterparts, which could benefit minorities. DC Studio – While most Americans still view today's job market struggles as temporary, major employers are quietly rebuilding their workforce strategies around AI-driven productivity increases — along with massive labor reductions. The revolution that's coming won't just change how we work, it will also upend who works at all. The data tells a stark story. McKinsey researchers project that 60%-70% of worker activities could be automated in the next three years. Goldman Sachs predicts 'significant disruption' affecting 300 million jobs in the US and Europe. The World Economic Forum estimates 85 million positions eliminated by the end of 2025. This AI revolution will also shatter the very assumptions on which diversity, equity and inclusion frameworks have been built. 5 According to the Dept. of Labor, minorities such as Latinos and African-Americans are more heavily represented in blue-collar professions such as construction, nursing and being security guards. These are jobs AI will have a far-harder time replacing. For decades, DEI operated under a prescriptive model: Expand access to elite education and professional careers seen as bastions of privilege where White people disproportionately benefit from systemic advantages. The 'knowledge economy' was framed as the promised land, and entry into white-collar strongholds — law, finance, tech, media — became the key to achieving both individual mobility and group equity for underrepresented groups. But what happens when AI targets those very professions for elimination? The evidence is clear: The occupations most vulnerable to AI displacement aren't blue-collar; they're white-collar, knowledge-economy jobs. Goldman Sachs' analysis shows that administrative support roles face 46% automation potential, legal work 44% and architecture and engineering 37%. Meanwhile, installation, maintenance and repair jobs face only 4% automation potential, and construction 6%. This creates a policy conundrum: How viable will any DEI model be when the majority of jobs lost are among 'privileged' white-collar workers? Traditional identity-based frameworks become inadequate when both Ivy League graduates and high-school-educated workers face simultaneous displacement. 5 Goldman Sachs' analysis shows that administrative support roles face 46% automation potential, legal work 44% and architecture and engineering 37%. Tierney – Paradoxically, the AI revolution may also usher in an era where blue-collar work offers more security than white-collar careers. Plumbers, electricians, HVAC technicians, and other tradespeople operate in unpredictable physical environments, precisely the conditions AI and robotics struggle to navigate. These are also fields where people of color are not underrepresented. According to Bureau of Labor Statistics data, Black workers constitute substantial portions of certain skilled trades, including nursing assistants (38%), security guards (36%) and transit drivers (33%). Similarly, BLS data finds that Hispanic workers are 'substantially overrepresented' in skilled trades like painting (59%), construction labor (51%) and carpentry (42%). As AI disrupts the economic security of college-educated professionals, it may, ironically, elevate sectors that DEI initiatives have largely overlooked. 5 Author Monica Harris says that AI challenges the value of human labor, and forces society to reconsider what makes us valuable beyond our economic output. Athena Lonsdale For the Black community, this economic shift has an important historical parallel. When enslaved Americans in Texas finally received news of their emancipation on June 19, 1865, many chose to forge pathways to economic advancement through skilled trades and entrepreneurship. Recognizing that financial independence was essential to freedom, they built sustainable livelihoods as blacksmiths, carpenters, seamstresses and business owners. Similarly, today's AI revolution may once again elevate trades and practical skills as crucial avenues of economic security for Blacks forced to pivot in a changing landscape. Today, the impact of AI challenges fundamental assumptions underlying DEI initiatives and necessitates an expanded framework for inclusion. It also invites a mandate to prepare all workers to thrive in an AI-mediated economy — not by chasing a shrinking number of office jobs, but by redefining what inclusion means in a post-white-collar era. This includes rethinking vocational education, investing in digital fluency across sectors and honoring skilled trades not as fallback options, but as integral components of a resilient and equitable workforce. 5 The workforce revolution brought about by AI may once elevate trades and practical skills as crucial avenues of economic security for African-Americans. Dearix – The coming disruption isn't just technological; it's philosophical. As AI challenges the value of human labor, it will force us to reconsider what makes us valuable beyond our economic output. This recognition of our common humanity could serve as the foundation for a new kind of inclusion, one defined by our shared vulnerability, adaptability and inherent dignity in a machine-accelerated world. We can approach the AI revolution as competing members of identity groups fighting for diminishing economic opportunities, or as a nation confronting a fundamental shift in how we define our worth and purpose. The latter path offers the possibility that in facing a common technological challenge, we might finally focus on what unites us rather than what divides us. Monica Harris is executive director of Fair For All.
